Inhaled Voriconazole For Prevention Of Invasive Pulmonary Aspergillosis
Access full-text files
Date
2009-06
Authors
Tolman, Justin A.
Wiederhold, Nathan P.
McConville, Jason T.
Najvar, Laura K.
Bocanegra, Rosie
Peters, Jay I.
Coalson, Jacqueline J.
Graybill, John R.
Patterson, Thomas F.
Williams, Robert O.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Targeted airway delivery of antifungals as prophylaxis against invasive aspergillosis may lead to high lung drug concentrations while avoiding toxicities associated with systemically administered agents. We evaluated the effectiveness of aerosolizing the intravenous formulation of voriconazole as prophylaxis against invasive pulmonary aspergillosis caused by Aspergillus fumigatus in an established murine model. Inhaled voriconazole significantly improved survival and limited the extent of invasive disease, as assessed by histopathology, compared to control and amphotericin B treatments.
Department
Description
LCSH Subject Headings
Citation
Tolman, J. A., Wiederhold, N. P., McConville, J. T., Najvar, L. K., Bocanegra, R., Peters, J. I., Williams, R. O. (Jun., 2009). Inhaled Voriconazole for Prevention of Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 53(6), 2613–2615. doi:10.1128/AAC.01657-08